Alberto Gil-Jimenez
Overview
Explore the profile of Alberto Gil-Jimenez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
207
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chelushkin M, van Dorp J, van Wilpe S, Seignette I, Mellema J, Alkemade M, et al.
Clin Cancer Res
. 2024 Jul;
30(18):4227-4239.
PMID: 39047168
Purpose: Platinum-based chemotherapy and immune checkpoint inhibitors are key components of systemic treatment for muscle-invasive and advanced urothelial cancer. The ideal integration of these two treatment modalities remains unclear as...
2.
Gil-Jimenez A, van Dijk N, Vos J, Lubeck Y, van Montfoort M, Peters D, et al.
Nat Commun
. 2024 Mar;
15(1):2538.
PMID: 38514623
Immune checkpoint inhibitors (ICI) can achieve remarkable responses in urothelial cancer (UC), which may depend on tumor microenvironment (TME) characteristics. However, the relationship between the TME, usually characterized by immune...
3.
Rijnders M, Nakauma-Gonzalez J, Robbrecht D, Gil-Jimenez A, Balcioglu H, Oostvogels A, et al.
Nat Commun
. 2024 Feb;
15(1):1349.
PMID: 38355607
Immune checkpoint inhibitors (ICI) improve overall survival in patients with metastatic urothelial cancer (mUC), but therapeutic success at the individual patient level varies significantly. Here we identify predictive markers of...
4.
de Vries H, Rafael T, Gil-Jimenez A, de Feijter J, Bekers E, van der Laan E, et al.
J Clin Oncol
. 2023 Jul;
41(31):4872-4880.
PMID: 37487169
Purpose: Patients with advanced penile squamous cell carcinoma have a poor prognosis (21% 2-year overall survival [OS] from diagnosis). We assessed the activity of atezolizumab (anti-PD-L1) in patients with advanced...
5.
Gil-Jimenez A, van Dorp J, Contreras-Sanz A, van der Vos K, Vis D, Braaf L, et al.
Eur Urol
. 2023 Mar;
83(6):e165.
PMID: 36907692
No abstract available.
6.
Gil-Jimenez A, van Dorp J, Contreras-Sanz A, van der Vos K, Vis D, Braaf L, et al.
Eur Urol
. 2022 Aug;
83(4):313-317.
PMID: 35965206
Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy is recommended for patients with muscle-invasive bladder cancer (MIBC). It has been shown that somatic deleterious mutations in ERCC2, gain-of-function mutations in...
7.
van Dijk N, Gil-Jimenez A, Silina K, van Montfoort M, Einerhand S, Jonkman L, et al.
Front Immunol
. 2022 Jan;
12:793964.
PMID: 34987518
Candidate immune biomarkers have been proposed for predicting response to immunotherapy in urothelial cancer (UC). Yet, these biomarkers are imperfect and lack predictive power. A comprehensive overview of the tumor...
8.
van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit L, de Feijter J, et al.
Nat Med
. 2020 Oct;
26(12):1839-1844.
PMID: 33046870
Preoperative immunotherapy with anti-PD1 plus anti-CTLA4 antibodies has shown remarkable pathological responses in melanoma and colorectal cancer. In NABUCCO (ClinicalTrials.gov: NCT03387761 ), a single-arm feasibility trial, 24 patients with stage...